List of Excipients in Branded Drug TERBUTALINE SULFATE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
ANI Pharmaceuticals Inc	TERBUTALINE SULFATE	terbutaline sulfate	62559-721	CELLULOSE, MICROCRYSTALLINE
ANI Pharmaceuticals Inc	TERBUTALINE SULFATE	terbutaline sulfate	62559-721	LACTOSE MONOHYDRATE
ANI Pharmaceuticals Inc	TERBUTALINE SULFATE	terbutaline sulfate	62559-721	MAGNESIUM STEARATE

Generic Drugs Containing TERBUTALINE SULFATE

Company	Ingredient	NDC	Excipient
Amneal Pharmaceuticals of New York LLC	terbutaline sulfate	0115-2611	ANHYDROUS LACTOSE
Amneal Pharmaceuticals of New York LLC	terbutaline sulfate	0115-2611	CELLULOSE, MICROCRYSTALLINE
Amneal Pharmaceuticals of New York LLC	terbutaline sulfate	0115-2611	HYPROMELLOSE 2910

What are the Most Frequently-Used Excipients in TERBUTALINE SULFATE?

# Of NDCs	Excipient
7	ANHYDROUS LACTOSE
10	CELLULOSE, MICROCRYSTALLINE
4	EDETATE DISODIUM

Terbutaline Sulfate Excipient Strategy and Commercial Opportunities

Last updated: October 4, 2026

Terbutaline sulfate is an established, low-cost beta-2 adrenergic agonist with limited remaining regulatory exclusivity and a largely generic competitive market. Commercial value is concentrated in formulation execution: stable oral tablets, preservative-free injectable products, pediatric dosing, unit-dose hospital packaging, and non-U.S. inhalation or nebulization products.

The strongest opportunities are unlikely to come from new chemical-entity patents. They are more likely to arise from differentiated delivery, improved tolerability, reliable supply, regulatory compliance, and targeted institutional distribution.

What is terbutaline sulfate and how is it used?

Terbutaline sulfate is the sulfate salt of terbutaline, a short-acting beta-2 adrenergic agonist. It relaxes bronchial smooth muscle and is used primarily for bronchospasm associated with asthma and other reversible obstructive airway conditions.

In the United States, labeled dosage forms have included:

Dosage form	Typical strength	Primary use	Commercial status
Oral tablet	2.5 mg and 5 mg	Bronchospasm	Generic market
Injection	1 mg/mL	Acute bronchospasm and selected hospital uses	Generic or institutional market
Inhaled or nebulized products	Country-dependent	Bronchodilation	More relevant outside the U.S.

Terbutaline is also used off-label as a tocolytic. The FDA has warned against prolonged outpatient use of oral or injectable terbutaline for preterm labor because of serious maternal cardiovascular risks. The agency has not approved terbutaline for prevention or treatment of preterm labor.[1]

What excipient properties matter most for terbutaline sulfate?

Terbutaline sulfate is a water-soluble ionic salt. Its excipient strategy should prioritize chemical stability, moisture control, tablet robustness, dose uniformity, injection compatibility, and patient tolerability.

Oral formulation considerations

The main development risks for terbutaline sulfate tablets are not poor aqueous solubility. They are low-dose uniformity, segregation, moisture sensitivity, powder flow, and degradation during storage.

A practical immediate-release tablet platform may include:

Formulation function	Candidate excipients	Development rationale
Diluent	Lactose monohydrate, microcrystalline cellulose, mannitol, dibasic calcium phosphate	Provides tablet mass and improves manufacturability
Binder	Povidone, copovidone, hydroxypropyl cellulose	Supports granule strength and content uniformity
Disintegrant	Croscarmellose sodium, crospovidone, sodium starch glycolate	Promotes rapid tablet breakup
Glidant	Colloidal silicon dioxide	Improves flow and die filling
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces sticking and ejection force
Taste modifier	Mannitol, sweeteners, flavors	Relevant to chewable or orally disintegrating products
Film coat	Hypromellose, polyvinyl alcohol, polyethylene glycol	Controls handling, appearance, and moisture exposure

For low-strength 2.5 mg tablets, direct compression may be possible if the API is adequately milled and blended. Wet granulation can improve content uniformity and flow but adds water and thermal processing. A dry-granulation or roller-compaction process may reduce moisture exposure and simplify scale-up.

The selected process should be evaluated for:

• Assay and content uniformity across commercial-scale batches.
• Terbutaline sulfate segregation during hopper discharge.
• Interaction between the sulfate salt and alkaline excipients.
• Tablet hardness, friability, disintegration, and dissolution.
• Stability under high humidity.
• Extractables and leachables from blister and bottle packaging.

Injectable formulation considerations

Terbutaline sulfate injection places greater demands on excipient control. A typical sterile aqueous product may use water for injection and sodium chloride for tonicity adjustment, with pH adjustment using a suitable acid or base. The final formula must be established through compatibility and stability studies rather than copied from a tablet formulation.

Key requirements include:

• Sterility and bacterial endotoxin control.
• Particulate-matter compliance.
• Control of pH and osmolality.
• Compatibility with glass vials, ampoules, syringes, and elastomeric closures.
• Protection from oxidation and light if stability data indicate sensitivity.
• Preservative-free presentation for neonatal, pediatric, or repeated hospital use where appropriate.

Benzyl alcohol and other preservatives require careful assessment because of age-related safety concerns. A preservative-free single-dose vial or ampoule can support hospital and pediatric positioning, although it increases packaging and manufacturing cost.

What excipient strategy is best for terbutaline sulfate tablets?

A conventional immediate-release tablet is the lowest-risk commercial platform. The preferred development path is a low-moisture process using microcrystalline cellulose, a superdisintegrant, a controlled lubricant level, and moisture-protective packaging.

Recommended platform by product objective

Commercial objective	Preferred formulation approach	Main benefit
Lowest manufacturing cost	Direct compression with lactose or microcrystalline cellulose	Simple, scalable process
Improved content uniformity	Dry granulation or wet granulation	Better control of low-dose API distribution
Pediatric use	Dispersible, chewable, or orally disintegrating tablet	Easier administration
Moisture protection	Film coat plus alu-alu blister	Better shelf-life control
Premium differentiation	ODT, scored tablet, or unit-dose blister	Administration and adherence advantages
Hospital supply	Robust standard tablet in unit-dose packaging	Fewer dispensing errors

An orally disintegrating tablet could create a differentiated product, but it should not be treated as automatically superior. Terbutaline’s bitter or pharmacologically active taste may require taste-masking excipients, polymer coating, ion-exchange resin complexation, or flavor systems. These approaches can create new dissolution and dose-uniformity risks.

A scored 2.5 mg tablet may have greater commercial utility than an ODT if it supports dose titration and reduces the need for multiple strengths. Any scoring claim must meet FDA expectations for dose uniformity and tablet subdivision.

What excipients are suitable for pediatric terbutaline products?

Pediatric formulations have a clear unmet-use case because dosing flexibility and administration burden are material issues. Candidate products include:

• Low-dose dispersible tablets.
• Oral granules or powder for reconstitution.
• Sugar-free oral solutions.
• Unit-dose oral syringes.
• Orally disintegrating tablets.

Liquid products require special attention to microbial preservation, viscosity, sedimentation, dosing-device accuracy, and taste. A sugar-free system based on sorbitol, glycerol, or other polyols may improve diabetic suitability but can introduce gastrointestinal tolerability issues.

High-risk excipient categories include:

• Benzyl alcohol in young children.
• Propylene glycol at elevated exposure.
• Ethanol in pediatric products.
• High polyol concentrations.
• Artificial colors where institutional or regional restrictions apply.

A pediatric product with a calibrated oral syringe, low excipient burden, and clear concentration labeling could compete more effectively than another conventional tablet.

What patents protect terbutaline sulfate products?

Terbutaline sulfate itself is an old active pharmaceutical ingredient. The original composition-of-matter and basic therapeutic-use patent position has expired in major markets.

U.S. Orange Book status

The FDA Orange Book is the relevant source for listed patents and regulatory exclusivity associated with approved small-molecule products. Generic terbutaline sulfate products generally compete through the abbreviated new drug application pathway rather than through an innovator patent estate.[2]

For current products, the commercially relevant patent questions are:

1. Whether an individual NDA or reference-listed drug has any active Orange Book patent listing.
2. Whether a later formulation has a separately listed delivery or dosage-form patent.
3. Whether a manufacturer has asserted non-Orange-Book process, trade-secret, or packaging rights.
4. Whether state or federal litigation affects a particular supplier.

No meaningful U.S. composition-of-matter barrier is expected for standard terbutaline sulfate tablets or injectable products. Patent status must still be checked against the current FDA Orange Book and applicable national registers before launch.

Formulation and method-of-use patents

Potential patentable subject matter could include:

• Extended-release terbutaline delivery.
• Orally disintegrating or taste-masked tablets.
• Nebulizer suspensions or inhalation solutions.
• Specific particle-size distributions.
• Device-specific delivery systems.
• Combination products.
• Manufacturing processes that produce a defined polymorph, impurity profile, or particle morphology.

A formulation patent would need meaningful technical differentiation. A claim covering routine excipient substitution, standard compression, or ordinary pH adjustment would face substantial validity and obviousness risks.

When does terbutaline sulfate lose exclusivity?

Terbutaline sulfate has already lost the principal exclusivity rights associated with an original small-molecule launch. The commercial market is therefore governed mainly by abbreviated approval, manufacturing capability, supply reliability, and product quality.

Exclusivity category	Current commercial relevance
New chemical entity exclusivity	Expired
Original composition patent	Expired
Standard tablet exclusivity	Generally expired
Standard injection exclusivity	Generally expired
Pediatric exclusivity	No current barrier expected for the mature product
Orphan-drug exclusivity	Not generally applicable to standard terbutaline products
Biosimilar exclusivity	Not applicable

Generic manufacturers may still obtain limited exclusivity for certain regulatory events, including a first Paragraph IV approval. That issue is product-specific and does not recreate broad protection for terbutaline sulfate.

Are there Paragraph IV challenges for terbutaline sulfate?

Paragraph IV litigation is most relevant when an ANDA applicant certifies that a listed patent is invalid, unenforceable, or not infringed. For a mature product with no significant active Orange Book patent estate, Paragraph IV activity is unlikely to be the central market issue.

If a new terbutaline formulation receives approval with listed patents, later ANDA applicants could challenge those patents. The most likely targets would be:

• Extended-release products.
• Inhalation formulations.
• Device-integrated products.
• Taste-masked or pediatric delivery systems.
• Combination products.

For standard immediate-release tablets and conventional injection, competition is more likely to proceed through ordinary ANDA filings and supplier substitution rather than high-value Paragraph IV litigation.

What is the FDA regulatory status of terbutaline sulfate?

Terbutaline sulfate is an established FDA-regulated prescription drug. Standard tablets and injection are associated with mature approval pathways and generic competition.

The regulatory strategy depends on the product:

Product	Likely FDA pathway
Conventional tablet equivalent	ANDA under section 505(j)
Conventional injection equivalent	ANDA if reference-product requirements are met
New dosage form with therapeutic equivalence challenge	505(b)(2) or NDA strategy
Novel inhalation device or delivery system	505(b)(2), NDA, and device requirements
Pediatric liquid without a direct reference equivalent	Potential 505(b)(2) strategy

The product must meet current requirements for chemistry, manufacturing, and controls, including impurity qualification, dissolution, stability, container closure, and process validation. FDA labeling must clearly distinguish approved bronchospasm indications from off-label obstetric use.

What manufacturing and intellectual-property barriers exist?

The API is commercially available from multiple sources, and ordinary tablet manufacturing does not present a major technical barrier. The more relevant barriers are operational.

Manufacturing risks

• Low-dose blend uniformity.
• API particle-size variability.
• Moisture-driven degradation.
• Sterile injectable processing.
• Container-closure compatibility.
• Supply continuity for sulfate salt API.
• Impurity control at commercial scale.
• Consistent dissolution across manufacturers.

Potential defensible assets

• A validated low-moisture process with superior stability.
• A pediatric formulation with demonstrated taste masking.
• A stable preservative-free injectable presentation.
• A differentiated inhalation product.
• A device and formulation combination.
• Proprietary impurity-control methods.
• Long-term supply contracts and qualified dual sourcing.

Trade secrets and process know-how may have more practical value than patents for a basic generic product. Those assets do not prevent competitors from independently developing an equivalent product, but they can reduce manufacturing cost and batch-failure risk.

Which commercial opportunities exist for terbutaline sulfate?

The strongest opportunities are niche-oriented rather than broad branded-generic launches.

1. Pediatric delivery

A dispersible tablet, low-volume oral solution, or taste-masked ODT could address administration problems. Commercial differentiation would depend on dosing accuracy, excipient safety, and institutional adoption.

2. Preservative-free injection

Hospitals may value a ready-to-use, preservative-free presentation with clear labeling, low extractables, and reliable supply. A prefilled syringe could improve workflow but would require device, container, and stability development.

3. Unit-dose packaging

Blistered tablets, hospital unit-dose cartons, and barcoded packaging could support institutional purchasing and reduce dispensing errors.

4. Inhalation and nebulization products

Terbutaline inhalation products are more commercially relevant in markets where they remain accepted or marketed. A nebulizer solution, metered-dose inhaler, or dry-powder inhaler could offer more meaningful differentiation than another oral tablet. Device compatibility, aerodynamic performance, dose uniformity, and local regulatory precedent would determine feasibility.

5. Supply-constrained generic positioning

A manufacturer with reliable API sourcing, dual manufacturing sites, and strong quality performance could win institutional contracts even without patent protection. The opportunity is strongest where incumbent suppliers have recurring shortages or limited presentations.

6. Combination products

Terbutaline could be evaluated in combination with other respiratory agents, but combination development would face clinical, regulatory, labeling, and commercial barriers. The product would need a clear therapeutic or adherence advantage over established beta-agonist combinations.

How does terbutaline sulfate compare with competing bronchodilators?

Terbutaline competes with albuterol, levalbuterol, fenoterol in selected markets, and longer-acting beta-2 agonists. Albuterol has broader U.S. market recognition and a larger inhalation-product ecosystem. Terbutaline’s potential advantages are its established oral and injectable use, low API cost, and utility in hospital settings.

Attribute	Terbutaline sulfate	Albuterol	Levalbuterol
Primary role	Short-acting beta-2 agonist	Short-acting beta-2 agonist	Short-acting beta-2 agonist
Oral availability	Established	Less central in current U.S. practice	Limited
Injectable opportunity	Established hospital use	Less prominent	Limited
Inhalation competition	Market-dependent	Strong	Established
Patent barrier for basic product	Low	Low for mature products	Low to moderate by product
Differentiation route	Pediatric, injectable, regional inhalation	Device and combination products	Device and stereochemical positioning

Terbutaline’s commercial weakness is limited differentiation in routine outpatient respiratory care. Its opportunity is stronger in targeted dosage forms and institutional supply.

What generic launch risks exist for terbutaline sulfate?

A new entrant faces several risks:

1. Low market price for standard tablets.
2. Established generic suppliers.
3. Limited prescribing growth.
4. Hospital purchasing pressure.
5. Regulatory scrutiny of injectable quality.
6. Potentially low annual revenue per SKU.
7. Substitution by albuterol and other bronchodilators.
8. Demand volatility caused by institutional tenders.
9. Packaging and stability costs that exceed the value of the product.
10. Limited protection for an ordinary formulation.

A launch is more attractive when the sponsor has an existing respiratory portfolio, hospital sales force, sterile manufacturing capacity, or a differentiated pediatric platform.

What is the revenue exposure for manufacturers?

Revenue exposure is generally modest for conventional terbutaline sulfate products because the molecule is mature and genericized. The economic case depends on volume, manufacturing cost, contract pricing, and channel access rather than premium pricing.

The most defensible revenue segments are:

• Hospital injection supply.
• Pediatric and caregiver-friendly formulations.
• Government and institutional tenders.
• Regional inhalation markets.
• Private-label or contract-manufactured products.
• Products bundled with respiratory delivery devices.

A stand-alone U.S. oral-tablet launch would likely require very low cost of goods and efficient distribution. A differentiated product can support better margins but requires additional clinical, formulation, device, or regulatory investment.

What is the patent strength of a new terbutaline formulation?

Patent strength depends on whether the product solves a measurable technical problem.

Proposed innovation	Likely patent strength
Substitution of one ordinary filler for another	Weak
Standard film coating	Weak
Defined moisture-stability system with comparative data	Moderate
Novel taste-masking architecture	Moderate to strong
New inhalation particle engineering	Moderate to strong
Device-specific dose-delivery system	Moderate
New therapeutic indication without clinical support	Weak
Stable preservative-free injectable platform	Moderate if technically unexpected
New combination product	Variable and data-dependent

The strongest claims would combine composition, process, performance, and clinical or stability data. A broad excipient-only claim is unlikely to provide durable exclusivity unless the formulation produces an unexpected result.

Key Takeaways

• Terbutaline sulfate is a mature generic beta-2 agonist with no meaningful original-patent barrier for standard tablets or injections.
• Excipient strategy should focus on moisture control, content uniformity, rapid disintegration, injection compatibility, and pediatric safety.
• Conventional tablets are low-cost but offer limited commercial differentiation.
• Pediatric dispersible, taste-masked, or orally disintegrating products have greater strategic value.
• Preservative-free injectable products and reliable hospital supply are credible institutional opportunities.
• Inhalation or nebulized products may support stronger differentiation in selected non-U.S. markets.
• Paragraph IV litigation is unlikely to define the standard terbutaline sulfate market unless a new formulation patent is listed.
• Process know-how, quality systems, supply reliability, and packaging may be more valuable than broad patent protection.
• The commercial case is strongest for companies with respiratory portfolios, sterile manufacturing, pediatric capabilities, or institutional distribution.

FAQs About Terbutaline Sulfate Formulation and Commercialization

Can terbutaline sulfate be formulated as an orally disintegrating tablet?

Yes. An ODT can be developed using superdisintegrants, porous fillers, taste-masking systems, and moisture-protective packaging. Taste, dose uniformity, and dissolution are the main development risks.

Is terbutaline sulfate suitable for a preservative-free injection?

Yes. A preservative-free single-dose vial, ampoule, or prefilled syringe is technically plausible. The product requires validated aseptic processing, container-closure studies, particulate control, and stability data.

Does terbutaline sulfate have biosimilar competition?

No. Terbutaline sulfate is a chemically synthesized small molecule, not a biologic. Competition proceeds through generic-drug pathways rather than biosimilar approval.

Can a new terbutaline inhaler receive patent protection?

Yes. Protection may be available for a novel formulation, particle-engineering process, dose-delivery system, or device combination. Patent strength depends on technical performance and non-obviousness.

Is terbutaline sulfate commercially attractive as a standard generic tablet?

Only under favorable cost and distribution conditions. The product has low formulation complexity but limited pricing power, established competitors, and substitution from other short-acting bronchodilators.

References

1. U.S. Food and Drug Administration. (2011). FDA drug safety communication: New warnings against use of terbutaline to treat preterm labor. https://www.fda.gov
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov
3. DailyMed. (2024). Terbutaline sulfate tablet and injection labeling. National Library of Medicine. https://dailymed.nlm.nih.gov
4. National Center for Biotechnology Information. (2024). Terbutaline. PubChem compound summary. https://pubchem.ncbi.nlm.nih.gov
5. U.S. Food and Drug Administration. (2023). ANDA submissions: Content and format. https://www.fda.gov